Safety and efficacy of HH2853, a novel EZH1/2 dual inhibitor, in patients with refractory solid tumours or non-Hodgkin lymphomas: a phase I study.

ABSTRACT:

Background

HH2853 is a novel dual EZH1/2 inhibitor that exhibits superior antitumour activity compared to tazemetostat across various preclinical models. Here, we evaluated the safety, pharmacokinetic (PK), pharmacodynamic (PD), and preliminary efficacy of HH2853 in patients with refractory advanced solid tumours and non-Hodgkin lymphomas (NHLs).

Methods

This open-label, global multicentre, phase I study was conducted at 12 centres in China and the USA, enrolling patients (aged ≥18 years) with relapsed or refractory solid tumours or NHLs. For dose escalation, seven predefined dose levels of HH2853 (50, 100, 200, 400, 600, 800, 1000 mg, orally twice daily for 28 days) were evaluated using a standard Bayesian optimal interval with accelerated titration design. Two dose levels

SUBMITTER: Fan Z 

PROVIDER: S-EPMC12354863 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature